Conexeu Sciences Inc.
For the period ended Jul 7, 2026. Filed Jul 7, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jul 7, 2026 · Filed Jul 7, 2026
Contents
EX-99.1 · References
References
Grand View Research, Aesthetic Injectable Market Report ($11.0B injectable aesthetics reference market).
Trademarks. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Conexeu is not affiliated with, endorsed by, or sponsored by Novo Nordisk. CXU™ and Ten-Minute Tissue™ are trademarks of Conexeu Sciences Inc.
Morgan Stanley, weight-loss drug (GLP-1) market outlook (roughly $79B in 2025 to approximately $190B by 2035).
4.Boston Consulting Group, Five Growth Imperatives for Medical Aesthetics in Times of Uncertainty, August 2025 (GLP-1-related aesthetic provider revenue $0.7B in 2025 to $2.0B by 2030).
- Peer-reviewed preclinical publications characterizing the CXU™ ECM platform: Hartwell R., et al., Tissue Engineering Part A (2015) 21(5); 1085-1094; Journal of Burn Care & Research (2019); Advances in Wound Care (2021) 10(3); 113-122; Pakyari M., et al., Experimental Dermatology (2021) 31; 715-724; Alnojeidi H., et al., Gels (2022) 8; 49; Amiri N., et al., Gels (2023) 9; 542.
Media Contact
Gateway Group
CNXU@Gateway-grp.com
949.574.3860
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.